A.P. Møller - Mærsk A/S
15.3.2021 13:12:04 CET | Globenewswire | Press release
| On 30 November 2020, A.P. Møller - Mærsk A/S (the Company) announced first phase of a share buy-back program in compliance with the EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). The share buy-back program of up to DKK 10bn is to be executed during a 15-month period beginning 1 December 2020. | |||
| During the first phase of the program running from 1 December 2020 up to 29 April 2021, the Company will buy-back A and B shares for an amount of up to DKK 3.3bn. | |||
| The following transactions have been made under the program in the period 8 March 2021 to 12 March 2021: | |||
| Number of A shares | Average purchase price A shares, DKK | Transaction value, A shares, DKK | |
| Accumulated, last announcement (market and A.P. Møller Holding A/S) | 32,425 | 404,563,969 | |
| 8 March 2021 | 250 | 12,167.7200 | 3,041,930 |
| 9 March 2021 | 240 | 12,666.0833 | 3,039,860 |
| 10 March 2021 | 240 | 12,852.6667 | 3,084,640 |
| 11 March 2021 | 230 | 13,163.0435 | 3,027,500 |
| 12 March 2021 | 230 | 13,112.9565 | 3,015,980 |
| Total 8-12 March 2021 | 1,190 | 15,209,910 | |
| Bought from A.P. Møller Holding A/S* 12 March 2021 | 1,261 | 12,781.4370 | 16,117,392 |
| Accumulated under the program (market and A. P. Møller Holding A/S) | 34,876 | 435,891,271 | |
| Number of B shares | Average purchase price B shares, DKK | Transaction value, B shares, DKK | |
| Accumulated, last announcement (market and A.P. Møller Holding A/S) | 129,660 | 1,744,620,554 | |
| 8 March 2021 | 1,200 | 13,007.6000 | 15,609,120 |
| 9 March 2021 | 1,200 | 13,566.3792 | 16,279,655 |
| 10 March 2021 | 1,200 | 13,748.9958 | 16,498,795 |
| 11 March 2021 | 1,250 | 14,127.2880 | 17,659,110 |
| 12 March 2021 | 1,150 | 14,035.9348 | 16,141,325 |
| Total 8-12 March 2021 | 6,000 | 82,188,005 | |
| Bought from A.P. Møller Holding A/S* 12 March 2021 | 3,841 | 13,698.0008 | 52,614,021 |
| Accumulated under the program (market and A. P. Møller Holding A/S) | 139,501 | 1,879,422,580 | |
| *) According to a separate agreement, A.P. Møller Holding A/S participates on a pro rata basis to the shares purchased in the share buy-back program. | |||
| With the transactions stated above, the Company owns a total of 143,746 A shares and 603,550 B shares as treasury shares, corresponding to 3.73% of the share capital. | |||
| | |||
| Details of each transaction are included as appendix. | |||
| Copenhagen, 15 March 2021 | |||
| Contact persons: | |||
| Head of Investor Relations, Stig Frederiksen, tel. +45 3363 3106 | |||
| Head of Media Relations, Signe Wagner, tel. +45 3363 1901 | |||
Attachments
- Announcement - Transactions in connection with share buy-back program (week 10 2021)
- Daily transactions - week 10
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Rocket Lab Corporation28.3.2026 11:39:53 CET | Press release
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency
Vivoryon Therapeutics N.V.28.3.2026 07:00:00 CET | Press release
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
